Mihael Polymeropoulos compensation by year
Vanda Pharmaceuticals Summary Compensation Table · all 10 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Salary | $618,000 | $675,000 | $700,000 | $721,000 | $746,235 | $769,000 | $815,140 | $897,000 | $933,000 | $965,655 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $2,900,000 | $2,900,000 | $1,237,200 | $1,237,200 | $679,200 | $2,332,200 | $1,306,400 | $810,750 | $1,971,000 | $2,007,000 |
| Option awards | $2,156,000 | $2,156,000 | $1,610,154 | $1,610,154 | $795,830 | $2,460,095 | $1,451,340 | $988,625 | $0 | $0 |
| Non-equity incentive | $1,483,200 | $502,200 | $700,000 | $675,000 | $656,687 | $596,744 | $658,633 | $983,112 | $947,928 | $834,326 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $28,257 | $32,789 | $37,322 | $34,783 | $35,468 | $36,118 | $37,897 | $40,728 | $44,313 | $44,487 |
| Total | $7,185,457 | $6,265,989 | $4,284,676 | $4,278,137 | $2,913,420 | $6,194,157 | $4,269,410 | $3,720,215 | $3,896,241 | $3,851,468 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Vanda Pharmaceuticals Inc. DEF 14A filed April 23, 2026, accession 0001628280-26-026893, and prior-year filings.
How this page was built: the Vanda Pharmaceuticals Inc. filed document, accession 0001628280-26-026893. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 450,000 | $3,969,000 | — |
| RSU | 337,500 | $2,976,750 | — |
| RSU | 57,500 | $507,150 | — |
| RSU | 28,750 | $253,575 | — |
| Option | 80,211 | — | $7.05 |
| Option | 11,462 | — | $11.36 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Vanda Pharmaceuticals Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Vanda Pharmaceuticals’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Mihael Polymeropoulos · this page | President, Chief Executive Officer and Chairman of the Board | $3,851,468 |
| Joakim Wijkstrom | Senior Vice President, Chief Marketing Officer | $1,457,528 |
| Timothy Williams | Senior Vice President, General Counsel and Secretary | $1,444,969 |
| Kevin Moran | Senior Vice President, Chief Financial Officer and Treasurer | $1,439,660 |
| Gunther Birznieks | Senior Vice President, Business Development | $1,415,471 |
Board service
Vanda Pharmaceuticals board · FY2021–FY2025How this board is paid
Company policy: Vanda Pharmaceuticals pays directors a $50,000 cash retainer and $260,000 in equity. As stated in Vanda Pharmaceuticals's FY2025 proxy.
The full Vanda Pharmaceuticals compensation record
free company briefThis page is one person within Vanda Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Vanda Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Vanda Pharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Vanda Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.